These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17112814)

  • 1. Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis.
    Sato K; Yamada E; Uehara Y; Takagi H; Mori M
    Clin Pharmacol Ther; 2006 Nov; 80(5):554-5. PubMed ID: 17112814
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical inquiries. Do COX-2 inhibitors worsen renal function?
    Wall R; Strickland C; Jamieson B; Lo V
    J Fam Pract; 2007 Nov; 56(11):957-8. PubMed ID: 17976347
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiac risks with COX-2 inhibitors.
    Ashworth AJ
    CMAJ; 2007 Feb; 176(4):489-92. PubMed ID: 17296963
    [No Abstract]   [Full Text] [Related]  

  • 4. The withdrawal of rofecoxib.
    Arellano FM
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
    [No Abstract]   [Full Text] [Related]  

  • 5. Rofecoxib in mild cognitive impairment.
    Ownby RL
    Curr Psychiatry Rep; 2006 Feb; 8(1):9-10. PubMed ID: 16513035
    [No Abstract]   [Full Text] [Related]  

  • 6. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
    Lynch PM
    Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
    [No Abstract]   [Full Text] [Related]  

  • 7. International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction.
    Metcalfe C; Wheeler BW; Gunnell D; Martin RM
    Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):778-85. PubMed ID: 20680998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient empowerment: rofecoxib revisited.
    Tannenbaum H
    J Rheumatol; 2006 Jun; 33(6):1033-5. PubMed ID: 16755647
    [No Abstract]   [Full Text] [Related]  

  • 9. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebrovascular events after discontinuation of rofecoxib treatment.
    Andersohn F
    Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824
    [No Abstract]   [Full Text] [Related]  

  • 11. Some key points emerging from the COX-2 controversy.
    Urquhart J
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):145-7. PubMed ID: 15654723
    [No Abstract]   [Full Text] [Related]  

  • 12. Vioxx should be allowed back on the market advises expert panel.
    Sibbald B
    CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435
    [No Abstract]   [Full Text] [Related]  

  • 13. Life after Vioxx.
    Underwood A
    Newsweek; 2005 Jan; 145(5):40-1. PubMed ID: 17896720
    [No Abstract]   [Full Text] [Related]  

  • 14. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
    Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs.
    Yan B; Leung Y; Urbanski SJ; Myers RP
    Can J Gastroenterol; 2006 May; 20(5):351-5. PubMed ID: 16691302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe acute cholestatic and cytolytic hepatitis induced by rofecoxib].
    Ouar S; Bellaïche G; Belloc J; Tordjman G; Ley G; Slama JL
    Gastroenterol Clin Biol; 2005 Apr; 29(4):471-2. PubMed ID: 15918218
    [No Abstract]   [Full Text] [Related]  

  • 17. The COX-2 inhibitors--an update.
    Furberg CD
    Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
    [No Abstract]   [Full Text] [Related]  

  • 18. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rofecoxib increases myocardial infarction risk in seniors].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032
    [No Abstract]   [Full Text] [Related]  

  • 20. COX-2 inhibitors and heart.
    Manoria P; Manoria PC
    Indian Heart J; 2005; 57(6):772-7. PubMed ID: 16521658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.